- Home
- PIII vs BCAB Comparison
PIII vs BCAB Comparison
Compare PIII & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- BCAB
- Stock Information
- Founded
- PIII 2015
- BCAB 2007
- Country
- PIII United States
- BCAB United States
- Employees
- PIII N/A
- BCAB N/A
- Industry
- PIII Medical/Nursing Services
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- PIII Health Care
- BCAB Health Care
- Exchange
- PIII Nasdaq
- BCAB Nasdaq
- Market Cap
- PIII 32.2M
- BCAB 28.6M
- IPO Year
- PIII N/A
- BCAB 2020
- Fundamental
- Price
- PIII $0.19
- BCAB $0.50
- Analyst Decision
- PIII Buy
- BCAB Buy
- Analyst Count
- PIII 3
- BCAB 2
- Target Price
- PIII $2.38
- BCAB $5.00
- AVG Volume (30 Days)
- PIII 5.4M
- BCAB 1.6M
- Earning Date
- PIII 11-12-2024
- BCAB 11-07-2024
- Dividend Yield
- PIII N/A
- BCAB N/A
- EPS Growth
- PIII N/A
- BCAB N/A
- EPS
- PIII N/A
- BCAB N/A
- Revenue
- PIII $1,476,630,000.00
- BCAB $11,000,000.00
- Revenue This Year
- PIII $21.45
- BCAB N/A
- Revenue Next Year
- PIII N/A
- BCAB N/A
- P/E Ratio
- PIII N/A
- BCAB N/A
- Revenue Growth
- PIII 25.38
- BCAB N/A
- 52 Week Low
- PIII $0.18
- BCAB $0.45
- 52 Week High
- PIII $1.35
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- PIII 39.59
- BCAB 23.87
- Support Level
- PIII $0.19
- BCAB $0.45
- Resistance Level
- PIII $0.29
- BCAB $0.52
- Average True Range (ATR)
- PIII 0.03
- BCAB 0.05
- MACD
- PIII -0.00
- BCAB 0.03
- Stochastic Oscillator
- PIII 4.30
- BCAB 20.73
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.